Free webinar: Lung cancer screening in Europe
September 27, 2022, 5 pm – 6:30 pm CET
Early detection of lung cancer can be life-saving.* What can we learn from countries that have already introduced screening programs? Join us as three academic experts share their insights on lung screening programs.
Lung cancer is the second most common cancer in the world. In the U.S. alone, more than 200,000 patients are diagnosed with this asymptomatic disease every year – and often far too late, leading to relatively low chances of survival.1 Regular lung cancer screenings enable physicians to detect tumors at earlier stages during which minimally invasive surgery might be more appropriate. However, when the lesions are small and deep, treatment using conventional two-room workflows can be challenging.2 This is because CT-based needle localization in the interventional suite followed by transfer to the OR involves risks such as needle dislocation, pneumothorax in an environment less safe than the OR itself,3 and patient anxiety during waiting times.
Our imaging systems with syngo software applications allow you to move ahead by expanding precision medicine in the treatment of lung cancer. Bringing CT-like imaging directly to the OR, ARTIS pheno can visualize even small lesions and distal airways as well as provide guidance throughout the procedure.2,4,5 Standardizing treatment for lung cancer to advance therapy outcomes has never been so firmly within reach.
Thoracic procedures with Hybrid OR imaging solutions
Installed in a Hybrid OR, ARTIS pheno offers a one-stop workflow for the resection of small pulmonary nodules. Dedicated features help you master even the most challenging aspects of treatment6 with image-guided video-assisted thoracoscopic surgery (iVATS)4 and image-guided endobronchial interventions. These approaches combine intraoperative large-volume 3D imaging, guidance followed by minimally invasive resection8, biopsy5, or ablation.9 The unique capabilities of ARTIS pheno enable thoracic surgeons to optimize clinical operations by reducing the overall procedure time10 and the time-at-risk for the patient.11
iVATS procedures in the Hybrid OR
Our one-stop Hybrid OR workflow with ARTIS pheno allows the patient to stay in the Hybrid OR throughout the entire procedure, potentially reducing time-at-risk by up to 94% compared to a CT-based two-room setup (single center study).7
Thanks to fast intraoperative 3D imaging with high spatial resolution as well as intraprocedural guidance tools, ARTIS pheno is the ideal system for performing endobronchial interventions.11 You can accomplish extremely precise tumor targeting with an effective lung radiation dose of only approximately 0.4 mSv 5 (single center study) compared to an effective dose of 1-2 mSv for typical chest CT screenings.12
Our Hybrid OR imaging solutions
Success story: The hybrid approach
Lung cancer is the leading cause of cancer death in Taiwan, affecting even nonsmokers at high rates. Thanks to widespread screenings in the recent past, an increasing number of patients with smaller lung nodules who are otherwise healthy are demanding state-of-the-art treatment for their condition. Chi Mei Medical Center, located in the city of Tainan, is able to provide cutting-edge minimally invasive procedures thanks to a commissioned Hybrid OR equipped with ARTIS pheno. Yao Fong, Head of Thoracic Surgery, says that the high-end robotic imaging system has allowed him and his team to improve lung cancer therapies and develop new treatment approaches.
Interview with Yao Fong, Director of Thoracic Surgery Department, Chi Mei Medical Center, Tainan, Taiwan